ONGENTYS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ONGENTYS (ONGENTYS).
Ongentys (opicapone) is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). By inhibiting COMT, it decreases the metabolism of levodopa to 3-O-methyldopa, thereby increasing plasma levodopa levels and enhancing its bioavailability in the brain, leading to improved dopaminergic effects.
| Metabolism | Primarily metabolized via glucuronidation (UGT1A9, UGT2B7, and UGT1A7) and sulfation (SULT1A1, SULT1E1). Minor metabolism by CYP3A4 and CYP2C9. |
| Excretion | Following oral administration, approximately 30% of the dose is excreted in urine as unchanged opicapone, with an additional 10% as glucuronide conjugates. The remainder is eliminated via biliary/fecal routes, accounting for about 60% of the dose. |
| Half-life | The terminal elimination half-life of opicapone is approximately 1 to 2 hours at low doses, but at therapeutic doses (50 mg) it exhibits nonlinear pharmacokinetics with an effective half-life of about 12 to 16 hours due to tight binding to COMT enzyme, allowing once-daily dosing. |
| Protein binding | Opicapone is highly bound to plasma proteins, primarily to albumin, with a bound fraction of approximately 99%. Binding is concentration-independent. |
| Volume of Distribution | The volume of distribution is approximately 0.3 L/kg, indicating distribution mainly into extracellular fluid. This low Vd is consistent with high protein binding and limited tissue penetration. |
| Bioavailability | The absolute oral bioavailability of opicapone is approximately 50% under fasting conditions. Food does not significantly affect the extent of absorption but may delay the rate. |
| Onset of Action | Inhibition of COMT activity in erythrocytes is observed within 1 hour after a single oral dose, with maximal inhibition reached at 2-3 hours. Clinical effects on levodopa pharmacokinetics are evident within the first dose. |
| Duration of Action | COMT inhibition persists for over 24 hours at steady state with once-daily dosing, supporting the once-daily regimen. Significant reduction in levodopa metabolism is maintained throughout the dosing interval. |
50 mg orally once daily, taken at bedtime.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not recommended for severe renal impairment (CrCl <30 mL/min) because of high metabolite exposure. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in moderate hepatic impairment (Child-Pugh class B); reduce dose to 25 mg once daily. No dose adjustment needed for mild impairment (Child-Pugh class A). |
| Pediatric use | Safety and efficacy not established in pediatric patients (<18 years); no recommended dosing. |
| Geriatric use | No specific dose adjustment required; but use with caution due to potential increased risk of hypotension and falls. Monitor renal function consistently. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ONGENTYS (ONGENTYS).
| Breastfeeding | No data on opicapone excretion in human milk. M/P ratio unknown. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment. |
| Teratogenic Risk | Pregnancy Category C. In animal studies, opicapone caused fetal developmental toxicity at maternally toxic doses. No adequate human studies exist. Risk cannot be ruled out in first trimester; potential benefits may warrant use despite risks. Second and third trimester risks are unknown. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Concomitant use with non-selective monoamine oxidase inhibitors (MAOIs) due to risk of hypertensive crisis","History of pheochromocytoma or other catecholamine-secreting tumors","Severe hepatic impairment"]
| Precautions | ["May cause orthostatic hypotension or syncope, especially when used with other dopaminergic drugs","May cause hallucinations or psychotic-like behavior","May worsen dyskinesia","May cause diarrhea, which can be severe and lead to dehydration","May cause somnolence and sudden sleep onset episodes","May increase risk of impulse control disorders (e.g., pathological gambling, hypersexuality)"] |
Loading safety data…
| Monitor for dopamine agonist effects (nausea, orthostatic hypotension, dyskinesia) and hepatic function. No specific fetal monitoring required beyond standard prenatal care. |
| Fertility Effects | In animal studies, opicapone reduced female fertility and caused prolonged estrus cycles at high doses. Human fertility effects unknown. |